<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01870609</url>
  </required_header>
  <id_info>
    <org_study_id>VS-6063-202</org_study_id>
    <nct_id>NCT01870609</nct_id>
  </id_info>
  <brief_title>Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma</brief_title>
  <acronym>COMMAND</acronym>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of
      defactinib (VS-6063) in subjects with malignant pleural mesothelioma (MPM) who have not
      progressed (confirmed partial response or stable disease) following ≥ 4 cycles of treatment
      with pemetrexed/cisplatin or pemetrexed/carboplatin. Prior to entry and randomization to the
      study, each subject must have tumor Merlin status(high or low) established by
      immunohistochemistry performed at a central laboratory. Subjects will be randomized in a 1:1
      ratio to receive oral VS-6063 400 mg twice per day, or matched placebo. Randomization will be
      stratified by tumor Merlin status (high versus low). Progression will be assessed both
      locally and by central review using the Response Evaluation Criteria In Solid Tumors (RECIST)
      Version 1.1. Subjects will continue to receive treatment until disease progression or other
      discontinuation criteria are met. Following documentation of nonfatal disease progression,
      all subjects will be followed for overall survival by telephone contact every 2 months until
      end of life or the close of the study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis-DSMB stated good safety profile but lack of efficacy
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the overall survival (OS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo</measure>
    <time_frame>From randomization to end of life, an expected average of 12 months</time_frame>
    <description>The median duration of OS will be estimated based on the 50th percentile of the Kaplan-Meier distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the progression free survival (PFS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo</measure>
    <time_frame>From date of randomization to earliest documented date of progression, an expected average of 4 months</time_frame>
    <description>PFS will be calculated based on the stratified log-rank test, and will use Kaplan-Meier estimation methods for estimation of summary statistics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess Quality of Life (QoL) in subjects treated with defactinib (VS-6063) or placebo using the Lung Cancer Symptom Scale modified for mesothelioma (LCSS-Meso)</measure>
    <time_frame>Every 3-4 weeks from baseline through end of treatment, an expected average of 4 months</time_frame>
    <description>QoL will be assessed using the LCSS-Meso. The LCSS-Meso total score will be analyzed through a comparison of median area under the curve (AUC) between the 2 treatment groups using a Wilcoxon test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the objective response rate (ORR) in subjects receiving defactinib (VS-6063) or placebo.</measure>
    <time_frame>Every 6-8 weeks from baseline through end of treatment, an expected average of 4 months</time_frame>
    <description>ORR is measured as the best overall response assessed by central review using Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determine the time to new lesion in subjects receiving defactinib (VS-6063) or placebo</measure>
    <time_frame>Every 6-8 weeks from baseline until end of treatment, an expected average of 4 months</time_frame>
    <description>Time to new lesion will be calculated from the date of randomization to the time of CT scan documenting a new lesion or date of other unambiguous indicator of new lesion development.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the relationship of defactinib (VS-6063) pharmacokinetics (PK) and outcome</measure>
    <time_frame>Time points at Week 4, Week 7, Week 10 and Week 13</time_frame>
    <description>PK parameters, including but not limited to plasma concentration, AUC (Area Under Curve) 0-t, Cmax, Tmax, and T1/2, compared with outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the population pharmacokinetics of defactinib (VS-6063) in subjects with malignant pleural mesothelioma</measure>
    <time_frame>Time points at Week 4, Week 7, Week 10 and Week 13</time_frame>
    <description>PK parameters, including but not limited to plasma concentration, AUC (Area Under Curve) 0-t, Cmax, Tmax, and T1/2</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the safety and tolerability of defactinib (VS-6063) in subjects with malignant pleural mesothelioma</measure>
    <time_frame>From start of treatment to end of treatment, an expected average of 4 months</time_frame>
    <description>Adverse events and their frequency, duration and severity, physical examination, laboratory parameters, vital signs and ECG change monitoring as determined based on CTCAE (Common Toxicity Criteria for Adverse Effects) 4.03</description>
  </other_outcome>
  <other_outcome>
    <measure>To collect EuroQol 5-Dimensional Health Questionnaire (EQ-5D) for health economics purposes</measure>
    <time_frame>Every 3-4 weeks from baseline through end of treatment, an expected average of 4 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">344</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>defactinib (VS-6063)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 x 200 mg defactinib (VS-6063) tablets, administered orally, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo tablets, administered orally, twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>defactinib (VS-6063)</intervention_name>
    <arm_group_label>defactinib (VS-6063)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic defactinib tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Able to understand and give written informed consent and comply with study
             procedures.

          -  2. Histologically proven diagnosis of MPM. All subjects must have biopsy material
             (archival tissue is acceptable) available for immunohistochemistry determination of
             Merlin status prior to enrollment.

          -  3. Evaluable disease, or measurable disease as assessed by RECIST version 1.1.

          -  4. Received only one prior chemotherapy regimen consisting of ≥ 4 cycles of
             pemetrexed/cisplatin or pemetrexed/carboplatin; subjects must have documentation of an
             ongoing response (confirmed PR or SD) following completion of this regimen. Subjects
             changing from cisplatin to carboplatin or vice versa within the same course of
             treatment because of platinum toxicity will be considered to have had first-line
             chemotherapy. Note: Subjects may have undergone previous surgical resection of their
             disease providing it was completed prior to initiation of chemotherapy.

          -  5. Received last dose of prior chemotherapy within ≤ 6 weeks of first dose of VS-6063.

          -  6. Have completed baseline quality of life evaluation as assessed by LCSS modified for
             mesothelioma

          -  7. Age ≥18 years.

          -  8. Life expectancy ≥3 months.

          -  9. All prior cytotoxic toxicities must have resolved to grade ≤ 1 prior to
             randomization.

          -  10. Performance status according to the Karnofsky Scale of ≥ 70% (after palliative
             measures such as pleural drainage).

          -  11. Corrected QT interval (QTc) &lt; 470 ms (as calculated by the Fridericia correction
             formula).

          -  12. Adequate bone marrow function (hemoglobin ≥ 9.0 g/dL; platelets ≥ 100 x 109/L;
             absolute neutrophil count [ANC] ≥ 1.5 x 109/L) without the use of hematopoietic growth
             factors.

          -  13. Adequate renal function (creatinine ≤ 1.5 x ULN [upper limit of normal] or
             glomerular filtration rate of ≥ 50mL/min).

          -  14. Adequate hepatic function (total bilirubin ≤ 1.5 x ULN for the institution;
             aspartate transaminase [AST] and alanine transaminase [ALT] ≤ 2.5 x ULN).

          -  15. Men and women of childbearing potential must agree to use adequate
             contraception(double barrier birth control) for the duration of study therapy and for
             3 months after the last dose of VS-6063.

        Exclusion Criteria:

          -  1. Currently enrolled in (or completed within 30 days before study drug
             administration)another investigational drug study.

          -  2. GI condition that could interfere with the swallowing or absorption of study drug.

          -  3. History of upper GI bleeding, ulceration, or perforation within 12 months prior to
             the first dose of study drug.

          -  4. Known history of Gilbert's Syndrome.

          -  5. Known history of stroke or cerebrovascular accident within 6 months prior to the
             first dose of study drug.

          -  6. Subjects with known infection with human immunodeficiency virus or Acquired Immune
             Deficiency Syndrome (testing not required).

          -  7. Subjects with known infection with hepatitis A, B or C (testing not required).

          -  8. Any evidence of serious active infections.

          -  9. Major surgery within 28 days prior to the first dose of study drug.

          -  10. Uncontrolled or severe concurrent medical condition (including uncontrolled brain
             metastases). Stable brain metastases either previously treated or being treated with a
             stable dose of steroids and/or anticonvulsants (no dose change within 28 days prior to
             the first dose of study drug) will be allowed.

          -  11. Uncontrolled or severe cardiovascular disease, including myocardial infarct or
             unstable angina within 6 months prior to study treatment, New York Heart Association
             Class II or greater congestive heart failure, serious arrhythmias requiring medication
             for treatment, clinically significant pericardial disease, or cardiac amyloidosis.

          -  12 Known history of malignant hypertension.

          -  13. Psychiatric illness or social situations that would limit compliance with study
             requirements.

          -  14. History of another invasive malignancy in the last 5 years. Adequately treated
             noninvasive,non-melanoma skin cancers as well as in situ carcinoma of the cervix
             within the last 5 years will be allowed.

          -  15. Prior treatment with drugs an FAK inhibitor.

          -  16. Women who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop Youssoufian</last_name>
    <role>Study Chair</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Oncology Centre</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse at RPA</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Cancer Center</name>
      <address>
        <city>East Bentlrigh</city>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epworth Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Cancer Institute</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital +61(0)7 3176 5054</name>
      <address>
        <city>Woolloongabba</city>
        <zip>QLD 4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL - St. Luc</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hopsital Ghent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven (University Hospitals Leuven)</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liege - Sart Tilman</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU, Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniche Humanitas Gavazzeni</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Rousai Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki University Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente, Enschede</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium MC</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Oncology Research Centre</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canterbury Regional Cancer &amp; Haematology Service</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Pulmonologii Ii Torakochirurgii w Bystrej</name>
      <address>
        <city>Bystra</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iatros International / Bloemfontein Medi-Clinic</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Oncology Centre of Rosebank</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Potter Oncology Center, Little Company of Mary Hospital</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Oncològic del Vallés Consorci Hospitalari Parc Tauli</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ensayos Clínicos Oncología</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Norte- Sanchinarro, Centro Integral Oncológico Clara Campal (CIOCC)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre</name>
      <address>
        <city>Bebington</city>
        <state>Wirral</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Hospital Cardiff</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broomfield Hospital</name>
      <address>
        <city>Chelmsford</city>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tayside Cancer Centre</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Oncology Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kent Oncology Centre, Maidstone Hospital</name>
      <address>
        <city>Kent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leicester</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>June 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <disposition_first_submitted>March 31, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 31, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 2, 2016</disposition_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

